Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q2 FY24 Earnings Presentation
17 slides from Eris Lifesciences's earnings presentation, Nov 8, 2023
Slide 1: Investor Presentation Filing Letter
EY Entrepreneur of the year-2Q13 2013 • FROST & SULLIVAN Best Fraclices-2013 Pis Badness today/YES bank Excellence Awards-2013 Eris Eris Lifesciences Limited Date: 08 November 2023 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra
Slide 2: Eris Lifesciences Limited Q2 FY24 and H1 FY24
Eris ERIS LIFESCIENCES LIMITED Q2 FY 24 and H1 FY 24 8th Nov 2023 M 1 tris
Slide 3: Acquisition of Biocon Nephrology and Dermatology Businesses
ACQUISITION OF BIOCON NEPHROLOGY AND DERMATOLOGY BUSINESSES OUR THESIS We have leveraged acquisitions Eris proposes to acquire to enter and quickly scale up our presence in new therapies BIOCON’s Nephrology and We have established our credentials in quick turnaround Dermatology businesses of under-o
Slide 4: Acquisition of Biocon Businesses – Entering Nephro; Consolidating Derma
ACQUISITION OF BIOCON BUSINESSES – ENTERING NEPHRO; CONSOLIDATING DERMA Biocon Businesses being acquired Nephrology Business Dermatology Business ▪ Total of 12 mother brands ▪ Total 9 mother brands ▪ Power brands Tacrograf and Renodapt - strong ▪ Leading brands – Psorid, Tbis, Picon, Calpsor play in
Slide 5: Nephrology – An Underserved Market with Significant Growth Potential
NEPHROLOGY – AN UNDERSERVED MARKET WITH SIGNIFICANT GROWTH POTENTIAL Key facts about Chronic Kidney Disease (CKD) in India • India has a Diabetic population of 100+ million and Hypertensive population of 220+ million • Diabetes and Hypertension are among the key drivers of Chronic Kidney The market
Slide 6: Nephrology – What the Biocon Business Brings to Us
NEPHROLOGY – WHAT THE BIOCON BUSINESS BRINGS TO US Q TACROGRAF TM CiaoSorb® BIONESP® ADDITIONAL GROWTH cf(it-RENODAPT t ER YPROTM LEVERS FOR US ▪ Power brands that give us ▪ USFDA-approved device ▪ Biologics – Established base for a strong entry into the in-licensed from Darbepoeitin Alfa & the laun
Slide 7: Derma - Addition of Biocon Brands Will Make Us the 2nd Largest in Psoriasis
DERMA - ADDITION OF BIOCON BRANDS WILL MAKE US THE 2nd LARGEST IN PSORIASIS Existing Portfolio – Key brands Additions from Biocon Deal Medical Dermatology is Cosvate (Clobetasol Propionate 0.0% o14 the largest segment of the Derma market consisting of the S 0 R VAT E° • Psoriasis is a INR following
Slide 8: Key Contours of the Biocon Transaction
KEY CONTOURS OF THE BIOCON TRANSACTION ▪ Eris has signed a definitive agreement to acquire the Dermatology & Nephrology businesses of Biocon Biologics Ltd. ▪ The scope of the acquisition includes the following aspects as a going concern: ▪ Nephrology business with a current revenue run-rate of INR 6
Slide 9: Strategic Priorities for FY24 – An Update at the End of Q2 FY24
STRATEGIC PRIORITIES FOR FY24 – AN UPDATE AT THE END OF Q2 FY24 Priority articulated at the start of the year Update at the end of Q2 FY24 1 • Successful commercialization of our • 2 combinations – Gliclazide-Dapagliflozin and New Product Pipeline Gliclazide-Sitagliptin – approved by the DCGI; launc
Slide 10: Two R&D Products Approved for Launch; Pipeline Expanded from 10 to 14
TWO R&D PRODUCTS APPROVED FOR LAUNCH; PIPELINE EXPANDED FROM 10 TO 14 r Candidates/ Therapy Development Status Commercialisation Active pipeline of 2 FDCs in Oral Anti-diabetes DCGI Permission Received Q3 of FY24 14 products 2 FDCs in Cardiovascular Disease Clinical Trials Q4 of FY24 • FDCs #12 • Ne
Slide 11: Branded Formulations Business Highlights – Q2 and H1 FY24
BRANDED FORMULATIONS BUSINESS HIGHLIGHTS – Q2 AND H1 FY24 FY23 FY24 Branded Formulations Revenue INR Mn Branded Formulations YPM INR lakh p.m. Branded Formulation Highlights - H1 FY24 'I 17% • 17% revenue growth in Branded 13% 9,470 17% Formulations - 97% of total revenue - 13% 8,116 5.1 4.5 4.2 4.9
Slide 12: Consolidated Income Statement - Q2 and H1 FY24
CONSOLIDATED INCOME STATEMENT - Q2 AND H1 FY24 Consolidated Q2 FY 24 H1 FY 24 INR Millions Q2 FY 24 Q2 FY 23 H1 FY 24 H1 FY 23 yoy Gr % yoy Gr % • Q2 FY24 operating revenue up by 10% to INR Sale of Products 5,005 4,553 9.9% 9,605 8,474 13.4% Other Operating Income 48 52 -7.7% 114 117 -2.9% 5,053 mil
Slide 13: Key Growth Drivers for FY24 – FY26
KEY GROWTH DRIVERS FOR FY 24 – FY 26 1 Growth in Base Business • Our Top-20 power brands account for 70% of our revenues and have grown at 11% in MAT Sep’23 13 out of these brands are ranked among the Top-5 in their respective segments. We have • 5 brands with revenues of Rs. 100+ crore each • 4 bra
Slide 14: Key Growth Drivers for FY24 – FY26 (Contd..)
KEY GROWTH DRIVERS FOR FY 24 – FY 26 (Contd..) • 3 Expansion of physician coverage • We continue to make good progress in expanding our coverage of Specialists and Consulting Physicians in line with our expectations • • We added ~ 200 Reps to the Eris field-force in FY23 4 Therapeutic Diversificatio
Slide 15: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors As on As on As on Name of Shareholder 29-Sep-23 30-Jun-23 31-Mar-23 Others 1.90% 876* *699 *572 FPIs Promoters 54.91% 52.86% 52.86% 13.20% 1 Chrys Capital (Emerald Investment Limited) 7.58% 7.58% 7.58% 2 UTI Mutual Fund
Slide 16: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 17: Thank You
Eris ERIS LIFESCIENCES LIMITED THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 16 Kris